EUCTR2004-004857-24-GB进行中（未招募）不适用
A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration
Pfizer Global Research and Development0 个研究点目标入组 144 人开始时间: 2005年2月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and/or female subjects nlt 55 years of age. Females must be of non-childbearing potential, ie, surgically sterilized or at least 2 years postmenopausal, and not breast-feeding
- •2.Subfoveal CNV with minimally classic CNV (classic component <50% of total lesion area) or occult CNV. Subjects with predominantly classic CNV (classic component nlt 50% of total lesion area) will be enrolled starting from stage 2. CNV must comprise at least nlt 50% of the total lesion area. (Lesion characteristics will be independently verified by a central reading center to determine eligibility)
- •3.For subjects with active occult neovascularization without any classic component:
- •a.Recent visual decline that in the opinion of the investigator is due to active AMD: subject report of recent visual decline with documentation of nlt 2 lines decline in visual acuity within 12 weeks OR
- •b.Subretinal blood or lipid deposition must be present, but must comprise <50% of the lesion OR
- •c.Growth of the lesion by at least 10% increase in its greatest linear dimension within 12 weeks
- •4.Some portion of the CNV must be under the center of the macula, as verified by the central reading center. If the center is obscured by blood and CNV surrounds the center (270° or more), CNV will be considered to be present under the center
- •5.No subfoveal fibrosis; total lesion fibrosis or scar must be nmt 25% total lesion area
- •6.Hemorrhage <50% of total lesion area
- •7.Total lesion area nmt 9 DA
- •8.ETDRS best-corrected visual acuity (BCVA) score in the study eye of 73 through 24 letters, inclusive (20/40 through 20/320)
- •9.Visual acuity score in the fellow eye of nlt 24 letters (20/320 or better)
- •10.Clear media and dilation to permit good stereo fundus photography
- •11.WHO performance status of 0, 1 or 2 (Appendix C)
- •12.Normal ECG or clinically non significant changes. Clinically non significant changes may include evidence of old myocardial infarction (MI), nonspecific ST changes, and old MI with RBBB etc.
- •13.Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Serous pigment epithelial detachment without surrounding neovascularization
- •2.Other serious ocular diseases or conditions, including diabetic retinopathy and glaucoma, that are likely to compromise visual acuity within 1 year
- •3.Prior subfoveal photocoagulation involving the center of the macula in the study eye; prior juxta-foveal photocoagulation is permitted
- •4.Prior intravitreal, sub-Tenon, or systemic therapy for AMD, with the exception of nutritional supplements
- •5.Subjects with prior transpupillary thermotherapy or intravitreal steroids in study eye or those likely to undergo these therapies within 6 months of the start of the study. One prior photodynamic therapy with Visudyne in the study eye is allowed if performed no more than three months before screening.
- •6.Retinal pigment epithelial tear in the study eye
- •7.Cataract surgery is indicated in study eye within 12 months
- •8.Intraocular surgery in study eye within past 3 months; eyelid surgery is permitted if well healed
- •9.Prior vitrectomy or submacular surgery in the study eye
- •10.Prior scleral buckling surgery in the study eye
- •11.Presence of ocular infection in the study eye
- •12.Presence of severe myopia (–6 diopters or greater) in the study eye
- •13.Undiagnosed acute illness first observed during screening or stable or severe concurrent medical conditions that, in the investigator's judgment, pose a safety liability, including evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease excluding untreated, asymptomatic, seasonal allergies at time of dosing
- •14.History of severe cardiac disease (New York Heart Association Class 3 or 4, unstable angina, MI within 6 months, ventricular tachycardia requiring treatment)15.Greater than Stage 1 mild hypertension defined as sitting blood pressure >159/99 mmHg on 2 out of 3 screening evaluations
- •16.Stroke within past 12 months
- •17.Physician diagnosed intermittent claudication
- •18.Prior radiation therapy to head or neck
- •19.Use of any investigational agent or participation in any other clinical trial in the past 60 days
- •20.Current use, use within the last 4 weeks, or likely need within 1 year of systemic glucocorticoids. (Dermal glucocorticoids are allowed.)
- •21.Current use or likely need within 1 year of treatment with anticoagulants (eg, warfarin) unless, in the opinion of the treating physician, the anticoagulants can be stopped at least 4 days before each sub-Tenon injection. (Anticoagulants can be resumed on the day following each sub-Tenon injection if no local hemorrhagic complication is evident.)
- •22.Allergy to or prior significant adverse reaction to fluorescein
- •23.Hemoglobin <10 g/dL, WBC <4 x 10 billion/L, platelets <150 x 10 billion/L at Screening
- •24.Creatinine or BUN >2 x upper limit of normal (ULN) at Screening
- •25.ALT, AST, and alkaline phosphatase >2 x ULN at Screening
- •26.Bilirubin >1.5 mg/dL at Screening
- •27.Proteinuria on urine dipstick greater than 1+ at Screening
- •28.Blood donation in excess of 500 mL within 60 days prior to the first dose of study medication.
- •29.History (within 180 days of screening) of alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 150 mL or 5 ounces of wine, 350 mL or 12 ounces of beer; or 44 mL or 1.5 ounces of hard liquor).
- •30.History of drug abuse within 180 days of Screening
研究者
相似试验
进行中（未招募）
1 期
Treatment of Thyroid Eye Disease with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study to observe safety and tolerability.Thyroid Eye Disease (TED)MedDRA version: 20.1Level: LLTClassification code 10057889Term: Graves' ophthalmopathySystem Organ Class: 100000004853EUCTR2020-005999-36-ITHORIZON THERAPEUTICS USA, INC.300
进行中（未招募）
1 期
Treatment of Thyroid Eye Disease with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study to observe safety and tolerabilityThyroid Eye Disease (TED)MedDRA version: 20.1Level: LLTClassification code 10057889Term: Graves' ophthalmopathySystem Organ Class: 100000004853EUCTR2020-005999-36-ESHorizon Therapeutics U.S.A., Inc.300
进行中（未招募）
1 期
/AMedDRA version: 20.1Level: LLTClassification code: 10057889Term: Graves' ophthalmopathy Class: 10015919Thyroid Eye DiseaseCTIS2024-515090-96-00Horizon Therapeutics Ireland Designated Activity Company295
进行中（未招募）
1 期
Treatment of Thyroid Eye Disease with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study to observe safety and tolerabilityEUCTR2020-005999-36-DEHorizon Therapeutics U.S.A., Inc.300
进行中（未招募）
1 期
A study to assess the safety, biological activity, tolerability and processing by the body of RO7200394 in participants with macular edema secondary to central retinal vein occlusioISRCTN15871371F. Hoffmann-La Roche Ltd50